Hangzhou Jiuyuan Genetic Biopharmaceutical (HKG:2566) said the Hong Kong bourse approved its application to convert and list 136.3 million unlisted shares in the city, according to a Friday filing.
Twelve investors hold the relevant shares and account for 56.44% of the drugmaker's total issued shares.
Upon completion of the conversion and listing, the pharma company's issued share capital will comprise 245.3 million H shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments